Skip to main content
Download PDF

Association of total bilirubin and indirect bilirubin content with metabolic syndrome among Kazakhs in Xinjiang

BMC Endocrine Disorders volume 20, Article number: 110 (2020) Cite this article

Abstract

Background

Some studies have shown that a high level of bilirubin is a protective factor against metabolic syndrome (MS), while a high level of transaminase is a risk factor for MS. However, the existing results are inconsistent and few cohort studies have been published.

Methods

Using an ambispective cohort study, 565 Kazakhs from Xinjiang, China were selected as the study subjects. The baseline serum bilirubin and transaminase levels of the subjects were divided into quartiles and the relationship between these values and the incidence of MS was analyzed. The definition of MS was based on the Joint Interim Statement (JIS) diagnostic criteria.

Results

The average follow-up time for the subjects was 5.72 years. The cumulative incidence of MS was 36.11% (204 of the 565 subjects), and the incidence density was 63.10/1000 person-years. Multivariate Cox regression analysis showed that the levels of total bilirubin (TBIL) and indirect bilirubin (IBIL) were negatively correlated with the occurrence of MS, Compared to the lowest quartile level (Q1), the hazard ratios of MS the TBIL levels at the Q2-Q4 quartiles were: 0.47 (0.31–0.71), 0.53 (0.35–0.79), and 0.48 (0.32–0.72), respectively, while IBIL levels at the Q2-Q4 quartiles showed an MS hazard ratio of 0.48 (0.32–0.72), 0.54(0.36–0.81), and 0.52 (0.35–0.77), respectively, all at a 95% confidence level. However, no relationship was found between transaminase levels and the incidence of MS.

Conclusion

Serum TBIL and IBIL levels were negatively correlated with the incidence of MS in a Kazakh population in China.

Peer Review reports

Background

Metabolic syndrome (MS) is a clustering of complex medical conditions, including hypertension, hyperglycemia, central obesity, hypertriglyceridemia, and high-density lipoprotein cholesterol (HDL-C) reduction. MS can lead to cardiovascular disease, type 2 diabetes, lipid disorder, liver steatosis, and other circulatory system disorders [1]. Although the etiology and pathogenesis of MS are not fully understood, it is generally believed that factors such as insulin resistance, inflammation, and oxidative stress play an important role in its occurrence and development [1,2,3]. Bilirubin, the main metabolite of heme, is toxic, and can cause irreversible damage to the brain and nervous system. Liver cells remove bilirubin from the body through its intake, transformation, and excretion. High levels of bilirubin in the serum indicate liver dysfunction. However, increasing evidence suggests that serum bilirubin has anti-inflammatory and antioxidant functions, and can also improve vascular endothelial function and enhance insulin sensitivity [4, 5], suggesting that a high level of bilirubin can protect against MS [6, 7]. Transaminase can promote inflammation and induce insulin resistance [8] and studies have shown that a high level of the transaminase alanine aminotransferase (ALT) is a risk factor for MS [6, 9]. One cohort study showed that γ-glutamyl transpeptidase levels in men and ALT levels in women are related to MS, but that direct bilirubin (DBIL), total bilirubin (TBIL), ALT, and aspartate aminotransferase (AST) levels in men and DBIL, TBIL, and AST levels in women are not [10]. However, further research is clearly needed on this topic, as the results of the previous studies are inconsistent.

Kazakhs in Xinjiang, China are nomadic minorities living primarily in remote mountainous areas. The majority fall into a low economic class and their culture and customs are significantly different from those of other ethnic groups [11, 12]. A previous study by our research group found the prevalence of MS in Kazakhs to be higher than that in other ethnic groups in Xinjiang and higher than the national average [13]. Therefore, this study used Xinjiang Kazakh residents as the research group and explored the relationship between the incidence of MS and serum bilirubin and transaminase levels. The results of this study provide potential advances for the early diagnosis and prevention of MS in the Xinjiang Kazakh population; our results may be extended to people living in Kazakhstan and Uzbekistan as well.

Methods

Research subjects

Based on the geographical distribution of Xinjiang’s ethnic minorities in northwestern China, a representative county (six villages in the Nalati Township, Xinyuan County) was selected and an ambispective cohort study was conducted on the local Kazakh population. The study baseline was conducted in 2009 and 2012 and a follow-up was performed in 2013, 2016, and 2017. The study included 785 Kazakh permanent residents aged 18 and over who voluntarily participated in the survey; 10 subjects with chronic liver disease, 2 subjects with cancer, and 208 subjects with MS at baseline were excluded from the study, resulting in a total of 565 subjects.

Epidemiological investigation and biochemical tests

At baseline and at each follow-up, a face-to-face interview was conducted by uniformly trained investigators to collect personal information, disease history, family history, and lifestyle behavior. Height, weight, waist circumference (WC), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were measured and recorded according to standardized methods. TBIL, DBIL, indirect bilirubin (IBIL), ALT, AST, fasting plasma glucose (FPG), triglyceride (TG), total cholesterol (TC), HDL-C, and low-density lipoprotein cholesterol (LDL-C) levels were measured using an automatic biochemical analyzer (Olympus Au 2700; Olympus diagnostics, Hamburg, Germany). Each subject signed an informed consent form. The investigation was approved by the ethics review committee of the First Affiliated Hospital of Shihezi University Medical College (IERB No. SHZ2010LL01), and the study methods were carried out in accordance with the relevant guidelines.

Definition of MS

Our identification of MS is based on the Joint Interim Statement (JIS) diagnostic criteria [14]. For MS to be diagnosed, three or more of the following indicators must be observed: (1) men WC ≥ 85 cm, women WC ≥ 80 cm; (2) SBP ≥ 130 mmHg or DBP ≥ 85 mmHg, have received treatment for hypertension, or have been previously diagnosed with hypertension; (3) FPG ≥ 5.6 mmol/L, have received treatment for type 2 diabetes, or have been previously diagnosed with type 2 diabetes. (4) TG ≥ 1.70 mmol/L or received treatment for elevated triglycerides; (5) men HDL-C < 1.0 mmol/L, women HDL-C < 1.30 mmol/L.

Statistical analysis

Data analysis was performed using SPSS version 20.0 (Chicago, Illinois, USA). Means ± standard deviations were used to describe continuous variables, and percentages were used to describe categorical variables. Rank sum tests were used to compare baseline characteristics between men and women, and chi-square tests were used to compare categorical variables. Serum bilirubin and transaminase levels in this population differed between men and women. Therefore, the baseline levels were separated into quartiles (Q1, Q2, Q3, and Q4) for each gender. The multivariate Cox proportional-hazards model was used to analyze the relationship between serum bilirubin or transaminase levels and MS. After adjusting for age and gender, the hazard ratio (HR) and 95% confidence interval (95% CI) of serum bilirubin and transaminase levels to MS were calculated. All statistical tests were bilateral and P < 0.05 indicated statistical significance.

Results

Baseline characteristics

A total of 565 subjects were included in this survey, including 221 males (39.1%). The average age of the population was 40.33 ± 11.86 years; the average age of men was significantly higher than that of women (men = 42.10 ± 12.93 years; women = 39.20 ± 10.99 years; P = 0.011). In a comparison of baseline characteristics between the two genders, the levels of WC, SBP, DBP, TG, TBIL, IBIL, ALT, and AST were higher in men than women, and HDL-C levels were higher in women than in men. These differences were statistically significant (P < 0.05). These data are shown in Table 1.

Table 1 Baseline characteristics based on different genders
Full size table

Incidence of MS

Follow-up was conducted with the subjects for 3233.04 person-years, with an average follow up time of 5.72 ± 1.49 years per subject. During this period, a total of 204 subjects developed MS, with a cumulative incidence of 36.11% (95% CI = 0.32–0.40) and an incidence density of 63.10/1000 person-years. Of the 221 men in the study, 70 developed MS, with a cumulative incidence of 31.67% (95% CI = 0.26–0.38) and an incidence density of 55.71/1000 person-years. The cumulative incidence increased with age (χ2 trend = 43.166, P < 0.001). Of the 344 women in this study, 134 developed MS, with a cumulative incidence of 38.95% (95% CI = 0.34–0.44) and an incidence density of 67.80/1000 person-years. The cumulative incidence again increased with age (χ2 trend = 76.391, P < 0.001). There was no statistically significant difference in the cumulative incidence and incidence density between men and women. These data are shown in Table 2.

Table 2 Comparison of the incidence of metabolic syndrome in different age groups
Full size table

Analysis of factors influencing MS

We divided the levels of serum bilirubin and transaminase into quartiles and examined the relationship between the different quartile levels and the risk of MS. There was no significant difference in the cumulative incidence of MS at different quartile levels. Using serum bilirubin and transaminase levels as independent variables and the occurrence of MS as the dependent variable for Cox proportional hazards model analysis and adjusting for age and gender, we found that TBIL and IBIL levels were negatively correlated with MS, but there was no correlation between the DBIL, ALT, or AST levels and MS (Table 3). Compared to the lowest quartile level (Q1), the HRs (95% CI) of TBIL Q2-Q4 levels were 0.47 (0.31–0.71), 0.53 (0.35–0.79), and 0.48 (0.32–0.72), respectively, and those of the IBIL Q2-Q4 levels were 0.48 (0.32–0.72), 0.54(0.36–0.81), and 0.52 (0.35–0.77), respectively. However, as shown in Table 3, there was no correlation between the DBIL, ALT, or AST levels and MS.

Table 3 Analysis of influencing factors for incident metabolic syndrome
Full size table

Correlation analysis of serum bilirubin and transaminase levels and MS at baseline with different components

In the populations with zero or one MS component at baseline, multivariate Cox regression analysis showed that the parameters shown in Table 4 are not related to the risk of MS. In the population with two MS components at baseline, TBIL and IBIL levels were negatively correlated with the risk of MS. Compared to the lowest quartile level (Q1), the risk HRs (95% CI) of the TBIL Q2-Q4 group were 0.35 (0.21, 0.60), 0.36 (0.21, 0.62), and 0.38 (0.22, 0.64), respectively, and those of the IBIL Q2-Q4 group were 0.31 (0.18–0.54), 0.39 (0.23–0.66), and 0.31 (0.18–0.54), respectively. However, DBIL, ALT, and AST levels were not related to the risk of MS (Table 4).

Table 4 Analysis of serum bilirubin, transaminase and MS at baseline with different components
Full size table

Discussion

In the Xinjiang Kazakh population, we determined the incidence of MS according to the JIS diagnostic criteria and analyzed the association of serum bilirubin and transaminase levels with MS. To our knowledge, the above study may be the first study for this specific population. The cumulative incidence of MS was 36.11% (95% CI = 0.32,0.40) and the incidence density was 63.10/1000 person-years. Recent studies have shown that the cumulative incidence of MS in China in 7 years was 18.55% [15] and the incidence density of MS in rural areas of South Korea was 30/1000 person-years for men and 46.4/1000 person-years for women [16]. The cumulative incidence and incidence density of MS in the Xinjiang Kazakh population are significantly higher than those in the groups mentioned above. This may be related to the unique genetic background, lifestyle, and eating habits of the Kazakh people. Staple foods of the Kazakh diet include roasted naan with flour and salt, cured meat (beef and mutton), and salty milk tea. In addition, women, especially, elderly women after marriage, rarely participate in work, field labor, and outdoor activities. The above factors lead to a higher incidence of hypertension, obesity, and dyslipidemia, which can explain the higher incidence of MS in the Kazakh population.

This study found that as the levels of TBIL and IBIL increase, the risk of MS is gradually reduced, suggesting that high levels of bilirubin have a protective effect against MS. Bilirubin is the main metabolite of heme and has long been considered a marker of liver dysfunction. Previous studies have shown that low levels of serum bilirubin increase the risk of cardiovascular diseases, diabetes, MS, obesity, and other diseases, while mildly increased serum bilirubin levels confer protection against these diseases [17]. Gilbert syndrome is a liver disorder characterized by benign hyperbilirubinemia, and studies have shown that Gilbert syndrome offers cardiovascular protection [18]. Studies have also shown that individuals with elevated bilirubin levels have a reduced risk of cardiovascular disease occurrence and death [19]. Bilirubin is recognized as the most effective endogenous antioxidant due to its continuous production in the bilirubin/biliverdin redox cycle, which can effectively scavenge hydrogen peroxide free radicals and inhibit lipid peroxidation of serum LDL [20, 21]. Bilirubin is 20 times more effective than the vitamin E analogue Trolox in preventing LDL oxidation [22]. Other studies have found that bilirubin has an anti-inflammatory effect. C-reactive protein (CRP) is a marker of chronic inflammation; several studies have shown that serum bilirubin levels are negatively correlated with CRP levels [23, 24]. Bilirubin can also inhibit the over-expression of vascular adhesion molecules induced by the inflammatory cytokine TNF-α [25]. In addition, mildly elevated bilirubin levels may increase insulin sensitivity. In experimental studies, bilirubin can improve the insulin sensitivity in leptin receptor-deficient and diet-induced mice with obesity [26, 27].

In view of the effects of bilirubin, some other studies have found a negative correlation between the total serum bilirubin levels and MS, which is consistent with the results of our study [7, 28, 29]. The results of some other studies, however, are not consistent with those of the current study. No correlation between baseline TBIL levels and MS was observed in Japanese men and women [30], and the relationship between the bilirubin subtype and MS was also inconsistent. A five-year cohort study in Chinese men showed that the levels of DBIL, but not those of TBIL and IBIL, were negatively correlated with MS [31]. This directly contradicts the results of the current study, which showed that serum levels of TBIL and IBIL, but not DBIL, were negatively correlated with MS. However, many studies have found that IBIL (also known as unconjugated bilirubin, UCB) has anti-inflammatory and anti-oxidant effects. In patients with Gilbert syndrome (increased serum UCB levels), serum bilirubin concentration was inversely related to the levels of oxidative stress markers [32]. Clinical research shows that elevated UCB levels can reduce the expression of pro-inflammatory cytokines and increase the body’s antioxidant capacity [33]. In addition, evidence from experimental studies in vitro and in vivo strongly supports the data obtained in human studies. A study on the treatment of experimental colitis in a rat model showed that UCB treatment reduced the inflammatory response induced by trinitrobenzene sulfonic acid and had a strong anti-inflammatory effect [34]. Hypochlorous acid (HOCl), an oxidant produced by myeloperoxidase (MPO), can induce protein and lipid oxidation. An in vitro experimental study showed that the addition of exogenous UCB to the serum and plasma of humans and rats can protect proteins and lipids from MPO-induced oxidation and reduce the production of chloramine and its decomposition products induced by HOCl and MPO [35].

Our study on the Kazakh population of Xinjiang did not show a relationship between transaminase levels and the risk of MS. This is inconsistent with the results of other studies [6, 9]. There are two possible explanations for this: (1) the sample size of the study population is small and/or the test efficiency is low; and (2) the genetics, diets, and living habits of the study population in our study are too different from those in the previous studies.

Our study found a negative correlation between TBIL or IBIL levels and the risk of MS in a study population with two MS components at baseline. In the study population with zero or one MS component at baseline, the levels of TBIL, IBIL, DBIL, ALT, and AST were not correlated with risk of MS. This may be due to the fact that when the research subject has two components of MS, the metabolic disorder is more severe. The serum bilirubin can clear superoxide and peroxidative free radicals produced due to MS, inhibit lipid peroxidation, and fight oxidative stress, thereby enhancing the protective effects, such as reduced inflammatory response.

There are some limitations of our research. First, the small sample size of this study may limit the validity of our findings. Second, we did not measure parameters of oxidative stress, inflammatory mediators, and bilirubin metabolism-related enzymes in the study subjects. Third, each subject’s bilirubin and transaminase levels were measured only once at each physical examination, which would not account for possible short-term fluctuations. Fourth, the present study did not collect information on comorbidities and medication use for data analysis.

Conclusions

This study found that serum TBIL and IBIL levels were negatively correlated with MS in the Kazakh population in Xinjiang, China; these findings may provide new options for the treatment and prevention of MS. Certain medications can be used to increase serum bilirubin levels, but there are safety concerns that will need to be addressed via further studies. Serum bilirubin levels may also be increased through nonpharmacological means, such as quitting smoking, weight loss, and the intake of the food supplement phycobilin [36, 37].

Availability of data and materials

The datasets generated during and/or analysed during the current study are not publicly available due the papers written using this dataset have not been published but are available from the corresponding author on reasonable request.

Abbreviations

MS:

Metabolic syndrome

JIS:

Joint Interim Statement

TBIL:

Total bilirubin

IBIL:

Indirect bilirubin

DBIL:

Direct bilirubin

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

WC:

Waist circumference

SBP:

Systolic blood pressure

DBP:

Diastolic blood pressure

FPG:

Fasting plasma glucose

TG:

Triglyceride

TC:

Total cholesterol

HDL-C:

High-density lipoprotein cholesterol

LDL-C:

Low-density lipoprotein cholesterol

HR:

Hazard ratio

95% CI:

95% confidence interval

CRP:

C-reactive protein

UCB:

Unconjugated bilirubin

HOCl:

Hypochlorous acid

MPO:

Myeloperoxidase

References

  1. Mendrick DL, Diehl AM, Topor LS, et al. Metabolic syndrome and associated diseases: from the bench to the clinic. Toxicol Sci. 2018;162(1):36–42.

    Article  CAS  PubMed  Google Scholar 

  2. Vona R, Gambardella L, Cittadini C, et al. Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxidative Med Cell Longev. 2019;2019:8267234.

    Article  Google Scholar 

  3. Mccracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14–20.

    Article  PubMed  Google Scholar 

  4. Cheriyath P, Gorrepati VS, Peters I, et al. High Total Bilirubin as a Protective Factor for Diabetes Mellitus: An Analysis of NHANES Data From 1999–2006. J Clin Med Res. 2010;2(5):201–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Wagner KH, Wallner M, Molzer C, et al. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clin Sci (Lond). 2015;129(1):1–25.

    Article  CAS  Google Scholar 

  6. Wang S, Zhang J, Zhu L, et al. Association between liver function and metabolic syndrome in Chinese men and women. Sci Rep. 2017;7:44844.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Shiraishi M, Tanaka M, Okada H, et al. Potential impact of the joint association of total bilirubin and gamma-glutamyltransferase with metabolic syndrome. Diabetol Metab Syndr. 2019;11:12.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis. 2007;191(2):391–6.

    Article  CAS  PubMed  Google Scholar 

  9. Lee SH, Cho DY, Joo NS, et al. The relationship of alanine aminotransferase to metabolic syndrome in a Korean population. Turk J Gastroenterol. 2018;29(1):52–60.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Pei D, Hsia TL, Chao TT, et al. Gamma-glutamyl transpeptidase in men and alanine aminotransferase in women are the most suitable parameters among liver function tests for the prediction of metabolic syndrome in nonviral hepatitis and nonfatty liver in the elderly. Saudi J Gastroenterol. 2015;21(3):158–64.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zhang XH, Zhang M, He J, et al. Comparison of anthropometric and Atherogenic indices as screening tools of metabolic syndrome in the Kazakh adult population in Xinjiang. Int J Environ Res Public Health. 2016;13(4):428.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Guo SX, Zhang XH, Zhang JY, et al. Visceral adiposity and anthropometric indicators as screening tools of metabolic syndrome among low income rural adults in Xinjiang. Sci Rep. 2016;6:36091.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Heng G, Rulin M, Jingyu Z, Dongsheng R, Shangzhi X, Feng S, Shuxia G. Comparison and analysis of epidemic characteristics of metabolic syndrome between Kazakh and Han ethnic groups in Xinjiang. Chin J Hypertension. 2011;19(06):538–43.

    Google Scholar 

  14. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and International Association for the Study of obesity. Circulation. 2009;120(16):1640–5.

    Article  CAS  PubMed  Google Scholar 

  15. Sun H, Liu Q, Wang X, et al. The longitudinal increments of serum alanine aminotransferase increased the incidence risk of metabolic syndrome: a large cohort population in China. Clin Chim Acta. 2019;488:242–7.

    Article  CAS  PubMed  Google Scholar 

  16. Hwang JH, Kam S, Shin JY, et al. Incidence of metabolic syndrome and relative importance of five components as a predictor of metabolic syndrome: 5-year follow-up study in Korea. J Korean Med Sci. 2013;28(12):1768–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Bulmer AC, Verkade HJ, Wagner KH. Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection. Prog Lipid Res. 2013;52(2):193–205.

    Article  CAS  PubMed  Google Scholar 

  19. Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. Am J Physiol Renal Physiol. 2014;307(2):123–36.

    Article  Google Scholar 

  20. Gazzin S, Vitek L, Watchko J, et al. A novel perspective on the biology of bilirubin in health and disease. Trends Mol Med. 2016;22(9):758–68.

    Article  CAS  PubMed  Google Scholar 

  21. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem. 1994;269(24):16712–9.

    CAS  PubMed  Google Scholar 

  22. Wu TW, Fung KP, Yang CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 1994;54(25):477–P481.

    Article  Google Scholar 

  23. Peng YF, Xie LQ, Xiang Y, et al. Serum bilirubin and their association with C-reactive protein in patients with migraine. J Clin Lab Anal. 2016;30(6):982–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhao X, Li L, Li X, et al. The relationship between serum bilirubin and inflammatory bowel disease. Mediat Inflamm. 2019;2019:5256460.

    Google Scholar 

  25. Mazzone GL, Rigato I, Ostrow JD, et al. Bilirubin inhibits the TNFalpha-related induction of three endothelial adhesion molecules. Biochem Biophys Res Commun. 2009;386(2):338–44.

    Article  CAS  PubMed  Google Scholar 

  26. Takei R, Inoue T, Sonoda N, et al. Bilirubin reduces visceral obesity and insulin resistance by suppression of inflammatory cytokines. PLoS One. 2019;14(10):e223302.

    Google Scholar 

  27. Dong H, Huang H, Yun X, et al. Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation. Endocrinology. 2014;155(3):818–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Huang SS, Chan WL, Leu HB, et al. Serum bilirubin levels predict future development of metabolic syndrome in healthy middle-aged nonsmoking men. Am J Med. 2015;128(10):1135–8.

    Article  Google Scholar 

  29. Kawamoto R, Kikuchi A, Akase T, et al. Total bilirubin independently predicts incident metabolic syndrome among community-dwelling women. Diabetes Metab Syndr. 2019;13(2):1329–34.

    Article  PubMed  Google Scholar 

  30. Oda E, Aizawa Y. Total bilirubin is inversely associated with metabolic syndrome but not a risk factor for metabolic syndrome in Japanese men and women. Acta Diabetol. 2013;50(3):417–22.

    Article  CAS  PubMed  Google Scholar 

  31. Li XH, Lin HY, Guan LY, et al. Direct bilirubin levels and risk of metabolic syndrome in healthy Chinese men. Biomed Res Int. 2017;2017:9621615.

    PubMed  PubMed Central  Google Scholar 

  32. Maruhashi T, Soga J, Fujimura N, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation. 2012;126(5):598–603.

    Article  CAS  PubMed  Google Scholar 

  33. Sundararaghavan VL, Binepal S, Stec DE, et al. Bilirubin, a new therapeutic for kidney transplant? Transplant Rev (Orlando). 2018;32(4):234–40.

    Article  PubMed Central  Google Scholar 

  34. Zhou JA, Jiang M, Yang X, et al. Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis. Mol Med Rep. 2017;16(2):1779–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Boon AC, Hawkins CL, Coombes JS, et al. Bilirubin scavenges chloramines and inhibits myeloperoxidase-induced protein/lipid oxidation in physiologically relevant hyperbilirubinemic serum. Free Radic Biol Med. 2015;86:259–68.

    Article  CAS  PubMed  Google Scholar 

  36. McCarty MF. “Iatrogenic Gilbert syndrome”--a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses. 2007;69(5):974–94.

    Article  CAS  PubMed  Google Scholar 

  37. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem. 2010;56(10):1535–43.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We sincerely thank those who participated in the study. We would also like to acknowledge the clinical laboratory of First Affiliated Hospital of Shihezi University School of Medicine for their work.

Funding

This study was funded by the National Natural Science Foundation of China (no. 81560551) and the Shihezi University Innovation Outstanding Young Talents Program (Natural Science) (no. CXPY201908). The funders played no role in the design of this study, the collection, analysis and interpretation of data or preparation of the manuscript.

Author information

Author notes

  1. Hao Hao and Heng Guo contributed equally to this work.

Authors and Affiliations

  1. Department of Public Health, Shihezi University School of Medicine, Shihezi, 832000, Xinjiang, China

    Hao Hao, Heng Guo, Ru-lin Ma, Yi-zhong Yan, Yun-hua Hu, Jiao-long Ma, Xiang-hui Zhang, Xin-ping Wang, Kui Wang, La-ti Mu, Yan-peng Song, Jing-yu Zhang, Jia He & Shu-xia Guo

  2. The First Affiliated Hospital of Shihezi University Medical College, Shihezi, 832000, Xinjiang, China

    Yan-peng Song

  3. Department of Pathology and Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, Shihezi, 832000, Xinjiang, China

    Shu-xia Guo

Authors
  1. Hao Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heng Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ru-lin Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi-zhong Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yun-hua Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiao-long Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiang-hui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xin-ping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. La-ti Mu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yan-peng Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jing-yu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jia He
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Shu-xia Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.G. conceived and designed the study, oversaw the data analysis, and edited the manuscript. H.H. played a role in data analyses and wrote the manuscript. H.H. and H.G., and played a large role in data collection and data analysis. R.M., Y.Y., Y.H., J. M., X.Z., X.W., K.W., L.M., Y.S., J.Z., J.H., H.G., and helped collect the data. The author(s) read and approved the final manuscript.

Corresponding authors

Correspondence to Jia He or Shu-xia Guo.

Ethics declarations

Ethics approval and consent to participate

Before participating in the study, all subjects signed informed consent. The study was approved by the Institutional Ethics Review Board (IERB) of the First Affiliated Hospital of Shihezi University School of Medicine (IERB No. SHZ2010LL01). The study was performed in accordance with the Helsinki Declaration.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hao, H., Guo, H., Ma, Rl. et al. Association of total bilirubin and indirect bilirubin content with metabolic syndrome among Kazakhs in Xinjiang. BMC Endocr Disord 20, 110 (2020). https://doi.org/10.1186/s12902-020-00563-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12902-020-00563-y

Keywords

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us